Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2025)

Gyre Therapeutics (GYRE) has disclosed Deferred Taxes for 3 consecutive years, with -$531000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Deferred Taxes changed N/A to -$531000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.6 million, a 98.52% decrease, with the full-year FY2024 number at -$1.0 million, up 13.62% from a year prior.
  • Deferred Taxes was -$531000.0 for Q3 2025 at Gyre Therapeutics, down from -$300000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of -$97000.0 in Q2 2024 to a low of -$592000.0 in Q4 2024.
  • A 3-year average of -$318400.0 and a median of -$306500.0 in 2024 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: surged 57.83% in 2024, then plummeted 209.28% in 2025.
  • Gyre Therapeutics' Deferred Taxes stood at -$403000.0 in 2023, then plummeted by 46.9% to -$592000.0 in 2024, then increased by 10.3% to -$531000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Deferred Taxes are -$531000.0 (Q3 2025), -$300000.0 (Q2 2025), and -$191000.0 (Q1 2025).